HALO Halozyme Therapeutics Inc.

If da 🧠 is on da outside n da $HALO shall protect YO then it shud begin to get obvious after last MNDY 🐑 AI news scuuuure.

$HALO Enjoy the bargain Mr. Market is offering. 6 new Enhanze deals in 2026, EPS CAGR of +35% plus, profit margin +75% and now with this pan- European win against Merck, an almost entirely de-risked new revenue stream from MDASE (for Keytruda SC and all other Alteogen partners). All of this is offered at a full year (2026) PE of 12!!! MDASE licensing earnings along with new Enhanze deals, Hypercon, Aerocon and HVAI also put to rest concerns over long term (mid to late 2030’s) earnings growth.

$HALO Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets WOO HOO !!!!!!

$HALO Analysts will have to start including MDASE revenue and profits in their forecasts. Don’t be surprised by a significant and sustained positive reaction to this win for weeks to come.

$HALO Whose going to ring HALO's doorbell first? HELLOOO HALO .... this is Mrs. and Mr. Merck - our attorney would like to chat. Other Major Pharma Companies Signed Up with Alteogen Several other global pharmaceutical companies have signed licensing or option agreements with Alteogen to use the ALT-B4 subcutaneous drug delivery platform: • Novartis: Signed a massive option and license agreement worth up to $3.22 billion in September 2026 to develop subcutaneous formulations across multiple Novartis products. • AstraZeneca: Signed an exclusive licensing deal worth up to $1.2 billion to $1.35 billion to develop subcutaneous oncology formulations. • Biogen: Partnered in a deal worth up to $579 million (with a $20 million upfront payment) to develop subcutaneous versions for up to two (plus an optional third) biologic products. • GSK (via Tesaro): Licensed the ALT-B4 enzyme in a deal worth up to $285 million to develop a subcutaneous version of its oncology drug Jemperli.

$HALO 5-6% haircut from the ATH of 116.84 A little digestion was needed and necessary after such a nice run. We might consolidate some more. Enjoy bargain shopping. 2026 full year PE of 11 PEG under 0.5 EPS CAGR of >35% Gross profit margin >75% Upcoming 2026-7 catalysts: -One more new partnership (guided by CEO for 2026) -Enhanze patent extension (which will lead to multi-year guidance update) -Hypercon trials (the start of which will reveal which therapeutics are involved and their TAMS). If the hypercon is used with blockbusters, don’t be surprised by another major run up -Dutch court decision on MDASE in Halozyme vs Merck affecting multiple EU countries. This is expected in early October.

Halozyme Therapeutics said a Dutch patent court ruled in its favor against Merck, ordering the drugmaker to stop manufacturing and selling injectable Keytruda in eight European markets: Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The Hague patent court found that Merck infringed a Halozyme patent covering MDASE, the company’s technology for rapid, high-volume subcutaneous drug delivery. The ruling could pressure Merck’s strategy for Keytruda SC, its subcutaneous formulation designed to support growth as patents protecting the original intravenous version approach expiration later this decade. Merck said it strongly disagrees with the Dutch court’s cross-border injunction, arguing that Halozyme’s patent is invalid globally and that the infringement claim has no merit. The company said it is evaluating its options. $HALO $MRK

🔥 $HALO — Halozyme Therapeutics 💥 BULLISH BREAKOUT + MAJOR CATALYST! $HALO is trading near its 52-week high, with the stock around $109.72 and above its 50-day moving average. Its MACD remains positive, while today's major legal victory against Merck adds another potential catalyst. Halozyme also recently reported record Q2 2026 results, with revenue up 48% YoY, and raised its full-year guidance. 🟢 SST BULLISH TAKE 🚀 Strong long-term uptrend 📈 Trading near 52-week highs ⚡ Positive MACD 💥 Major patent/legal catalyst 🔥 Strong earnings + raised guidance 🟢 Bullish momentum remains intact 👀 $PSQL & $HALO — TWO BULLISH STOCKS TO WATCH TODAY! Watch volume + price action + resistance breaks for confirmation. 🔥 Trade the setup. Not the hype.

$HALO Halozyme Therapeutics, Inc. - Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology

$HALO I must say this is one serious run! So glad I hung on to my shares when things were moving slowly!

$HALO HALO has been ranking as one of the strongest stocks in the whole market. Why? It's on a huge uptrend, AND company has solid fundamentals